Liminatus Pharma, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Liminatus Pharma, Inc. entered into a subscription agreement dated November 2, 2026, to sell common stock at $2.50 per share in a private placement. The agreement is with an unnamed subscriber (details on signature page). Closing is scheduled for November 20, 2026, with an outside date of December 31, 2026. The company commits to file a registration statement within 60 days of closing to register resale rights for the subscriber's shares.
Why this rating
Dollar amount not disclosed in template; boilerplate subscription agreement for private placement. Registration rights obligation standard but manageable. No material event details visible without signature page specifics.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.